Nancy Hutson

Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA.

Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation.

Endo Health Solutions, Inc. operates as holding company with interest in providing health care services. It offers pain management, pelvic health, urology, endocrinology and oncology services. The company was founded by Carol A. Ammon on November 18, 1997 and is headquartered in Malvern, PA.

Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation.

Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA.

Inspire Pharmaceuticals, Inc. operated as a biopharmaceutical company. It discovered and developed pharmaceutical products to treat diseases that results from deficiencies in the body's natural mechanisms of mucosal hydration. The company was founded by Kendall Harden, Richard C. Boucher, Andre L. Lamotte, H. Jefferson Leighton and Terrance G. McGuire and was headquartered in Whitehouse Station, NJ.

Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina.

Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA.

Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation.

Endo Health Solutions, Inc. operates as holding company with interest in providing health care services. It offers pain management, pelvic health, urology, endocrinology and oncology services. The company was founded by Carol A. Ammon on November 18, 1997 and is headquartered in Malvern, PA.

Inspire Pharmaceuticals, Inc. operated as a biopharmaceutical company. It discovered and developed pharmaceutical products to treat diseases that results from deficiencies in the body's natural mechanisms of mucosal hydration. The company was founded by Kendall Harden, Richard C. Boucher, Andre L. Lamotte, H. Jefferson Leighton and Terrance G. McGuire and was headquartered in Whitehouse Station, NJ.

Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation.

Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation.

Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina.

Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA.

Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina.

Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina.

Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina.